151751-Najiba-Chargi

396 CHAPTER 19 REFERENCES 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer sta - tistics 2018: GLOBOCAN estimates of in - cidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 2018;68(6):394-424. doi:10.3322/caac.21492 2. Stoyanov GS, Kitanova M, Dzhenkov DL, Ghenev P, Sapundzhiev N. Demograph - ics of Head and Neck Cancer Patients: A Single Institution Experience. Cureus . 2017;9(7):e1418. doi:10.7759/cureus.1418 3. Boje CR. Impact of comorbidity on treat - ment outcome in head and neck squamous cell carcinoma - a systematic review. Radio- ther Oncol . 2014;110(1):81-90. doi:10.1016/j. radonc.2013.07.005 4. Argiris A, Karamouzis M V, Raben D, Ferris RL. Head and neck cancer. Lancet (London, England) . 2008;371(9625):1695-1709. doi:10.1016/S0140-6736(08)60728-X 5. Mehanna H, West CML, Nutting C, Paleri V. Head and neck cancer--Part 2: Treat - ment and prognostic factors. BMJ . 2010;341:c4690. doi:10.1136/bmj.c4690 6. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slot - man BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with ra- diotherapy. J Clin Oncol . 2008;26(22):3770- 3776. doi:10.1200/JCO.2007.14.6647 7. Pottel L, Lycke M, Boterberg T, et al. Serial comprehensive geriatric assessment in elderly head and neck cancer patients undergoing curative radiotherapy identi- fies evolution of multidimensional health problems and is indicative of quality of life. Eur J Cancer Care (Engl) . 2014;23(3):401-412. doi:10.1111/ecc.12179 8. Ellis G, Whitehead MA, O’Neill D, Lang - horne P, Robinson D. Comprehensive geri - atric assessment for older adults admitted to hospital. Cochrane database Syst Rev . 2011;(7):CD006211. doi:10.1002/14651858. CD006211.pub2 9. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the Interna - tional Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol . 2005;55(3):241-252. doi:10.1016/j.critrevonc.2005.06.003 10. Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, vanMunster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol . 2012;13(10):e437-44. doi:10.1016/S1470-2045(12)70259-0 11. Zwart AT, van der Hoorn A, van Ooijen PMA, Steenbakkers RJHM, de Bock GH, Halmos GB. CT-measured skeletal muscle mass used to assess frailty in patients with head and neck cancer. J Cachexia Sarcopenia Muscle . 2019;10(5):1060-1069. doi:10.1002/ jcsm.12443 12. Reijnierse EM, Trappenburg MC, Blauw GJ, et al. Common Ground? The Concordance of Sarcopenia and Frailty Definitions. J Am Med Dir Assoc . 2016;17(4):371.e7-12. doi:10.1016/j.jamda.2016.01.013 13. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing . 2019;48(1):16-31. doi:10.1093/ageing/ afy169 14. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol . 2017;71:26-33. doi:10.1016/j.oraloncology.2017.05.012